Sirius Therapeutics has initiated a first-stage clinical study for an advanced, extended-duration Factor XI siRNA anticoagulant, aimed at addressing thromboembolic conditions.

Mirtazapine acts as an alpha-2 adrenergic receptor (ADRA2) antagonist, causing the release of norepinephrine and serotonin in the brain.

Takeda Pharmaceuticals and Protagonist Therapeutics have signed a global licensing and partnership deal for the advanced experimental blood disorder medication, Rusfertide.

Alprazolam is an agonist at the GABAA receptor, a key player in the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) pathway.

Jaguar Gene Therapy has received the green light from the FDA to initiate trials on JAG201 targeting a specific genetic variant associated with Autism Spectrum Disorder and Phelan-McDermid Syndrome.

Venlafaxine, an SNRI, targets SERT-5 and NET to regulate brain neurotransmitter balance.

Adaptimmune Reveals FDA Approval of Afami-cel Submission for Advanced Synovial Sarcoma Treatment with Expedited Review.

Dexamethasone, a small molecule drug molecule with a glucocorticoid receptor (GR) agonist action, has got all the science enthusiasts' tongues wagging.

Sandoz introduces Tyruko® (natalizumab), a first-of-its-kind biosimilar aimed at treating multiple sclerosis, now available in Germany.

Furosemide is a small molecule NKCC2 inhibitor drug, blocking the sodium-potassium-chloride co-transporter in the kidney's ascending loop of Henle.

Johnson & Johnson has filed an additional request with the FDA for authorization of its DARZALEX FASPRO formula as a therapy option for newly identified multiple myeloma cases eligible for transplant.

KLONOPIN (clonazepam) is a benzodiazepine medication that was first approved by the FDA in 1975 for the treatment of seizure disorders and panic disorder.